Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | -106.0K |
Gross Profit | 106.0K |
Operating Expense | 5,980.0K |
Operating I/L | -5,874.0K |
Other Income/Expense | -80.0K |
Interest Income | 0.0K |
Pretax | -5,954.0K |
Income Tax Expense | -82.0K |
Net Income/Loss | -5,954.0K |
Benitec Biopharma Inc. is a biotechnology company specializing in the development of DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. The company's main focus is on developing gene therapy agents such as BB-301 for treating oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.